Package 73141-021-02

{"route": ["ORAL"], "spl_id": "32becc54-372f-b7eb-e063-6294a90a48b0", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "upc": ["0373141021020", "0373141022027"], "unii": ["A6IEZ5M406"], "rxcui": ["616749", "728231"], "spl_set_id": ["9fb62878-c76a-4be2-99be-962ce2956af2"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["A2A Integrated Pharmaceuticals"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "60 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73141-021-02)", "package_ndc": "73141-021-02", "marketing_start_date": "20250408"}], "brand_name": "RANOLAZINE", "product_id": "73141-021_32becc54-372f-b7eb-e063-6294a90a48b0", "dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "73141-021", "generic_name": "RANOLAZINE", "labeler_name": "A2A Integrated Pharmaceuticals", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "RANOLAZINE", "active_ingredients": [{"name": "RANOLAZINE", "strength": "500 mg/1"}], "application_number": "ANDA213517", "marketing_category": "ANDA", "marketing_start_date": "20250408", "listing_expiration_date": "20261231"}